Dapagliflozin in Heart Failure with Reduced Ejection Fraction: A Real-World Study
Aims: We aimed to observe the improvements in cardiac function indexes and the occurrence of adverse events in patients with heart failure with reduced ejection fraction (HFrEF) after dapagliflozin administration in a real-world setting. Methods: We retrospectively included 201 patients with HFrEF...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Compuscript Ltd
2022-08-01
|
| Series: | Cardiovascular Innovations and Applications |
| Online Access: | https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2022.0005 |